Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Infect Dis Clin North Am ; 15(3): 983-1002, xi, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11570149

ABSTRACT

This article reviews the pharmacokinetics of antibacterial agents in patients with normal and decreased renal function. The concepts of volume and distribution, rate of elimination, loading and maintenance doses, and therapeutic drug monitoring are delineated. Special reference is made to the intermittent dosing of cefazolin with hemodialysis. Newer, as well as traditional methods of extracorporeal circulation and the resultant changes in antibacterial agent pharmacodynamics are discussed.


Subject(s)
Anti-Infective Agents/therapeutic use , Renal Insufficiency/drug therapy , Anti-Infective Agents/pharmacokinetics , Contraindications , Humans , Kidney/metabolism , Mathematics , Peritoneal Dialysis , Renal Dialysis , Renal Insufficiency/therapy
2.
Infect Dis Clin North Am ; 14(2): 371-90, ix, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10829261

ABSTRACT

This article provides information on the pharmacokinetics of antibacterial agents in patients with normal renal function and those with impaired renal function. Specific discussion includes the use of serum levels, dosage adjustments in dialysis, new strategies for cefazolin dosages in dialysis patients, and antibiotic toxicity in renal failure, and tabular data is presented for determining appropriate dosages for varying degrees of renal failure.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/therapeutic use , Renal Insufficiency/complications , Renal Insufficiency/metabolism , Anti-Bacterial Agents/administration & dosage , Bacterial Infections/drug therapy , Bacterial Infections/metabolism , Biological Availability , Humans , Kidney Function Tests , Renal Replacement Therapy
4.
JAMA ; 282(17): 1627-32, 1999 Nov 03.
Article in English | MEDLINE | ID: mdl-10553788

ABSTRACT

CONTEXT: Despite suppressive treatment with highly active antiretroviral therapy (HAART), replication-competent virus can still be isolated from peripheral blood mononuclear cells and genital cells of many individuals receiving suppressive HAART. OBJECTIVE: To determine whether free virion RNA can be detected in the blood plasma and/or genital tract fluids from patients receiving suppressive HAART. DESIGN: Prospective cohort study conducted from November 1998 to May 1999. SETTING: Academic medical center. PATIENTS: Human immunodeficiency virus 1-infected individuals (20 men and 2 women) shown in our laboratories to have fewer than 50 copies/mL of HIV-1 RNA in peripheral blood plasma while taking suppressive HAART. MAIN OUTCOME MEASURES: Free virion RNA levels in peripheral blood plasma and genital fluids, quantified using an ultrasensitive reverse transcriptase polymerase chain reaction able to quantify cell-free virion RNA to a lower limit of 5 copies/mL and qualitatively detect viral RNA below this level. RESULTS: In all 22 patients, residual viral RNA could be detected in the peripheral blood plasma (mean level, 17 copies/mL). The presence of viral RNA suggests that ongoing viral replication is occurring, albeit at low levels, in each patient evaluated. Viral RNA levels were lower in most patients' genital fluids compared with blood plasma and in 12 patients were undetectable. CONCLUSIONS: These data suggest that low-level replication of HIV-1 in patients taking suppressive HAART may be demonstrated not only in peripheral blood mononuclear cells but also in peripheral plasma as cell-free virion RNA. Complete ablation of viral replication may require intensification of antiretroviral therapies beyond standard suppressive HAART.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/blood , HIV Infections/drug therapy , HIV-1/genetics , RNA, Viral/blood , Body Fluids/virology , Drug Therapy, Combination , Female , HIV Infections/virology , HIV-1/physiology , Humans , Male , Prospective Studies , RNA, Viral/analysis , Reverse Transcriptase Polymerase Chain Reaction , Semen/virology , Vagina , Virus Replication
5.
N Engl J Med ; 339(25): 1803-9, 1998 Dec 17.
Article in English | MEDLINE | ID: mdl-9854115

ABSTRACT

BACKGROUND: Highly active antiretroviral therapy can effectively decrease the levels of human immunodeficiency virus type 1 (HIV-1) virions in peripheral plasma and seminal fluid of infected men. Whether the genital tract of HIV-1-infected men who are receiving highly active antiretroviral therapy and who have no detectable virus in the peripheral plasma harbors replication-competent virus is not known. METHODS: We collected peripheral-blood and semen samples from seven men with HIV-1 infections who were receiving highly active antiretroviral therapy and who had no detectable viral RNA (fewer than 50 copies per milliliter) in plasma and analyzed the samples for cell-associated proviral DNA using a quantitative polymerase-chain-reaction assay. Replication-competent viruses were evaluated by cell-coculture assays. Proviral DNA and replication-competent virus obtained from peripheral-blood and seminal cells were also analyzed by sequencing relevant viral genes. RESULTS: Despite the long-term suppression of HIV-1 RNA in the plasma of the seven men, proviral DNA was detected in seminal cells in four. Replication-competent viruses were recovered from peripheral-blood cells in three men and from the seminal cells in two of these three men. The viruses recovered from the seminal cells had no genotypic mutations suggestive of resistance to antiretroviral drugs and were macrophage-tropic, a feature that is characteristic of HIV-1 strains that are capable of being sexually transmitted. CONCLUSIONS: In HIV-1-infected men who are receiving highly active antiretroviral therapy and who have no detectable levels of viral RNA in plasma the virus may be present in seminal cells and therefore may be capable of being transmitted sexually.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV-1/isolation & purification , Proviruses/isolation & purification , Semen/virology , Amino Acid Sequence , DNA, Viral/blood , DNA, Viral/isolation & purification , Drug Resistance, Microbial , Drug Therapy, Combination , HIV Infections/transmission , HIV Infections/virology , HIV-1/genetics , HIV-1/growth & development , Humans , Male , Molecular Sequence Data , RNA, Viral/blood , Virus Replication
6.
Infect Dis Clin North Am ; 9(3): 591-614, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7490435

ABSTRACT

This article provides background information on the pharmacokinetics of antimicrobial agents in patients with normal and impaired renal function. Tables are provided to allow quick determination of appropriate dosages for varying degrees of renal failure. Specific mention is made of aminoglycoside dosing, dosage adjustment in dialysis, and antibiotic toxicity in renal failure.


Subject(s)
Anti-Infective Agents/pharmacokinetics , Renal Insufficiency/metabolism , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/adverse effects , Hemofiltration , Humans , Renal Dialysis
7.
J Antimicrob Chemother ; 35(6): 765-73, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7559188

ABSTRACT

Cefepime is a broad-spectrum cephalosporin that is reported to have enhanced activity against ceftazidime-resistant Gram-negative bacilli. In this study the effects of varying inoculum size on in-vitro susceptibility to cefepime and other selected antimicrobial agents were determined by agar dilution MICs and in time-kill studies. Among strains of Pseudomonas aeruginosa (n = 55) and Enterobacter spp (n = 56) that had previously been identified as ceftazidime-resistant, 73% and 96% were susceptible to cefepime (MIC < or = 16 mg/L), respectively, when tested with an inoculum of 10(4) cfu. However, with an inoculum of 10(7) cfu, 98% and 100% of strains were resistant, respectively. Furthermore, the bactericidal activity of cefepime against ceftazidime-resistant isolates was also inoculum-dependent. In time-kill studies, bactericidal action was obtained only at the lowest concentration of organisms (10(4) cfu/mL). beta-Lactamase extracted from an isolate of P. aeruginosa that demonstrated an inoculum effect had a lower affinity for cefepime than for ceftazidime. Overall, cefepime proved to be more resistant to hydrolysis by the beta-lactamase. However, differences in kinetics of the beta-lactamase against cefepime or ceftazidime do not appear to be of consequence in determining susceptibility of P. aeruginosa and Enterobacter spp. at high bacterial densities, since most strains with chromosomally-mediated beta-lactamase are highly resistant.


Subject(s)
Ceftazidime/pharmacology , Cephalosporin Resistance , Cephalosporins/pharmacology , Gram-Negative Bacteria/drug effects , Cefepime , Enterobacter/drug effects , Enterobacter cloacae/drug effects , Gram-Negative Bacteria/enzymology , Kinetics , Microbial Sensitivity Tests , Pseudomonas aeruginosa/drug effects , beta-Lactamases/metabolism
8.
Antimicrob Agents Chemother ; 37(10): 2069-73, 1993 Oct.
Article in English | MEDLINE | ID: mdl-8257125

ABSTRACT

We compared ciprofloxacin, rifampin, and gentamicin treatments, alone and in combination, for 5 days in the therapy of experimental aortic valve endocarditis in rats caused by a clinical isolate of vancomycin-resistant Enterococcus faecium. The MICs and MBCs of vancomycin, ciprofloxacin, rifampin, and gentamicin were 250 and > 1,000, 3.1 and 6.3, 0.098 and 1.6, and 12.5 and > 50 micrograms/ml, respectively. Infected rats were sacrificed after completing 5 days of therapy. Additional rats within each treatment group were followed for 5 days beyond the last dose of antibiotic therapy. Although survivals in the different groups were not significantly different after 5 days of therapy, survival was significantly better 5 days beyond the last dose of antibiotic therapy in rats treated with rifampin-containing regimens. The combination of ciprofloxacin and gentamicin was bactericidal in vitro and in vegetations from rats with enterococcal endocarditis. Rifampin alone was similarly bactericidal in vivo, but it was not significantly better than rifampin in combination with other antibiotics. Subpopulations resistant to rifampin, but not ciprofloxacin, were detected in the inoculum and in most vegetations during therapy. However, the combination of ciprofloxacin plus both gentamicin and rifampin reduced both the rifampin-susceptible and -resistant population in vegetations of 9 of 10 animals below the level of detection after 5 days of therapy. Nevertheless, a residual enterococcal population apparently remained in numbers of < 2 log10 CFU/g after 5 days of therapy, which resulted in relapse. Perhaps a longer course of therapy would have eliminated this residual population and improved efficacy.


Subject(s)
Ampicillin Resistance , Ciprofloxacin/pharmacology , Endocarditis, Bacterial/drug therapy , Endocarditis, Bacterial/microbiology , Enterococcus faecalis , Gentamicins/pharmacology , Gram-Positive Bacterial Infections , Rifampin/pharmacology , Vancomycin/pharmacology , Animals , Ciprofloxacin/blood , Disease Models, Animal , Drug Resistance, Microbial , Drug Therapy, Combination/pharmacology , Enterococcus faecalis/drug effects , Enterococcus faecalis/physiology , Gentamicins/blood , Male , Microbial Sensitivity Tests , Rats , Rats, Sprague-Dawley , Rifampin/blood
10.
Ann Intern Med ; 117(2): 112-6, 1992 Jul 15.
Article in English | MEDLINE | ID: mdl-1605425

ABSTRACT

OBJECTIVES: To describe an epidemic of vancomycin-resistant Enterococcus faecium causing bacteremia and bacteriuria, to identify the source of infection, to delineate risk factors associated with acquisition of the organism, and to determine antibiotic sensitivities for the organism. DESIGN: Investigation of an epidemic, including a case-control study. SETTING: Medical-surgical intensive care unit and ward in a university medical center. PATIENTS: Nine patients infected or colonized with vancomycin-resistant Enterococcus faecium and 20 noninfected controls. MEASUREMENTS: Clinical data, environmental surveillance cultures, and in-vitro microbiologic studies. RESULTS: Colonization or infection by vancomycin-resistant E. faecium was associated with an increased duration of treatment with ceftazidime, 13.2 compared with 4.6 days, and a greater number of nonisolated days of hospitalization in the intensive care unit, 19.9 compared with 6.4 days for infected and noninfected patients, respectively (P less than 0.05). Environmental surveillance cultures recovered the organism repeatedly from the rectal probe handles of three electronic thermometers used exclusively on nonisolated patients in the intensive care unit. Restriction endonuclease analysis of plasmid DNA showed that all clinical and environmental isolates were identical. Infection control measures, including isolation of colonized or infected patients and removal of the rectal thermometer probes suspected to be responsible for transmission, resulted in termination of the outbreak. In-vitro, time-kill studies showed that the combination of ciprofloxacin, rifampin, and gentamicin resulted in bactericidal activity against the organism. CONCLUSIONS: This nosocomial outbreak of infection due to a highly vancomycin-resistant strain of Enterococcus is the first epidemic in which an electronic thermometer has been implicated as the vehicle of transmission for an infectious agent.


Subject(s)
Cross Infection/transmission , Enterococcus faecium/drug effects , Gram-Positive Bacterial Infections/transmission , Thermometers , Vancomycin/pharmacology , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , Cross Infection/microbiology , Disease Outbreaks , Drug Resistance, Microbial , Electronics, Medical , Equipment Contamination , Gram-Positive Bacterial Infections/microbiology , Hospital Bed Capacity, 300 to 499 , Hospitals, Teaching , Humans , Middle Aged , Odds Ratio , Population Surveillance , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...